These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
927 related items for PubMed ID: 11520074
1. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice. Yasuda T, Yoshimoto T, Tsubura A, Matsuzawa A. Cell Immunol; 2001 Jun 15; 210(2):77-86. PubMed ID: 11520074 [Abstract] [Full Text] [Related]
2. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. Takahashi S, Fossati L, Iwamoto M, Merino R, Motta R, Kobayakawa T, Izui S. J Clin Invest; 1996 Apr 01; 97(7):1597-604. PubMed ID: 8601623 [Abstract] [Full Text] [Related]
4. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A. J Rheumatol; 2010 Jan 15; 37(1):60-70. PubMed ID: 19955044 [Abstract] [Full Text] [Related]
5. Nephritogenicity of the lprcg gene on the MRL background. Kimura M, Ogata Y, Shimada K, Wakabayashi T, Onoda H, Katagiri T, Matsuzawa A. Immunology; 1992 Jul 15; 76(3):498-504. PubMed ID: 1526655 [Abstract] [Full Text] [Related]
7. IL-12-encoding plasmid has a beneficial effect on spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. Hagiwara E, Okubo T, Aoki I, Ohno S, Tsuji T, Ihata A, Ueda A, Shirai A, Okuda K, Miyazaki J, Ishigatsubo Y. Cytokine; 2000 Jul 15; 12(7):1035-41. PubMed ID: 10880249 [Abstract] [Full Text] [Related]
8. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. Steinmetz OM, Turner JE, Paust HJ, Lindner M, Peters A, Heiss K, Velden J, Hopfer H, Fehr S, Krieger T, Meyer-Schwesinger C, Meyer TN, Helmchen U, Mittrücker HW, Stahl RA, Panzer U. J Immunol; 2009 Oct 01; 183(7):4693-704. PubMed ID: 19734217 [Abstract] [Full Text] [Related]
9. FcgammaRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease. Yajima K, Nakamura A, Sugahara A, Takai T. Eur J Immunol; 2003 Apr 01; 33(4):1020-9. PubMed ID: 12672068 [Abstract] [Full Text] [Related]
10. Vaccination with autoreactive CD4(+)Th1 clones in lupus-prone MRL/Mp-Fas(lpr/lpr) mice. Fujii T, Okada M, Fujita Y, Sato T, Tanaka M, Usui T, Umehara H, Mimori T. J Autoimmun; 2009 Sep 01; 33(2):125-34. PubMed ID: 19596182 [Abstract] [Full Text] [Related]
11. Alleviation of renal disease and lymphadenopathy in MRL-Fasp(lrcg)/Fas(lprcg) (MR-lpr(cg)) mice neonatally infected with mouse mammary tumor virus encoding superantigen strongly reactive with TCR Vbeta8.2 element. Matsuzawa A, Yasuda T, Zhang Y, Nagase H, Yoshimoto T, Kimura M, Tsubura A. Viral Immunol; 2000 Sep 01; 13(3):297-311. PubMed ID: 11016595 [Abstract] [Full Text] [Related]
12. Contribution of major histocompatibility complex (MHC) to upregulation of anti-DNA antibody in transgenic mice. Song YW, Tsao BP, Hahn BH. J Autoimmun; 1993 Feb 01; 6(1):1-9. PubMed ID: 8457281 [Abstract] [Full Text] [Related]
13. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis. Faust J, Menke J, Kriegsmann J, Kelley VR, Mayet WJ, Galle PR, Schwarting A. Arthritis Rheum; 2002 Nov 01; 46(11):3083-95. PubMed ID: 12428253 [Abstract] [Full Text] [Related]
14. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S. J Rheumatol; 2002 Apr 01; 29(4):707-16. PubMed ID: 11950011 [Abstract] [Full Text] [Related]
15. Th1 versus Th2 immune responses in autoimmune lacrimal gland disease in MRL/Mp mice. Jabs DA, Lee B, Whittum-Hudson JA, Prendergast RA. Invest Ophthalmol Vis Sci; 2000 Mar 01; 41(3):826-31. PubMed ID: 10711700 [Abstract] [Full Text] [Related]
16. IgG1 and IgG2a production by autoimmune B cells treated in vitro with IL-4 and IFN-gamma. Klinman DM. J Immunol; 1990 Apr 01; 144(7):2529-34. PubMed ID: 2108205 [Abstract] [Full Text] [Related]
17. An epistatic effect of the female specific loci on the development of autoimmune vasculitis and antinuclear autoantibody in murine lupus. Zhang MC, Misu N, Furukawa H, Watanabe Y, Terada M, Komori H, Miyazaki T, Nose M, Ono M. Ann Rheum Dis; 2006 Apr 01; 65(4):495-500. PubMed ID: 16150787 [Abstract] [Full Text] [Related]
18. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Sadanaga A, Nakashima H, Akahoshi M, Masutani K, Miyake K, Igawa T, Sugiyama N, Niiro H, Harada M. Arthritis Rheum; 2007 May 01; 56(5):1618-28. PubMed ID: 17469144 [Abstract] [Full Text] [Related]
19. B cell apoptosis accelerates the onset of murine lupus. Trébéden-Nègre H, Weill B, Fournier C, Batteux F. Eur J Immunol; 2003 Jun 01; 33(6):1603-12. PubMed ID: 12778478 [Abstract] [Full Text] [Related]
20. A pivotal role of cell-bound but not soluble CD4 molecules in full development of lupus-like manifestations in MRL-Fas(lprcg)/Fas(lprcg) mice. Zhang Y, Yasuda T, Wang CR, Yoshimoto T, Nagase H, Takamoto M, Tsubura A, Kimura M, Matsuzawa A. Clin Exp Immunol; 2000 Oct 01; 122(1):124-32. PubMed ID: 11012628 [Abstract] [Full Text] [Related] Page: [Next] [New Search]